Fresenius, Plaintiffs ask for more time to settle suit

Fresenius is now working to settle a lawsuit brought against it by plaintiffs regarding its dialysate products GranuFlo and NaturaLyte. Although the company notified its own dialysis centers about cardiac arrest events in some patients using the products, it allegedly did not inform other dialysis centers at the same time it sent an internal memo, the New York Times reported.

The two Fresenius dialysates neutralize the normal buildup of acid in the blood.

In March 2016, reports noted that the company and plaintiffs asked a district court judge for more time to settle the multidistrict litigation (MDL) before scheduled trials are set to begin.

The company and the plaintiffs asked for a stay until August 31, 2016. “The requested stay of proceedings in this MDL and continuances of the first two bellwether trials are based upon good cause; they serve interests of judicial economy and promote litigation efficiency” as the parties attempt “to bring about a settlement-in-principle,” they wrote, as reported in